NASDAQ:FOLD

Amicus Therapeutics Stock Forecast, Price & News

$10.01
+0.08 (+0.81 %)
(As of 06/21/2021 11:27 AM ET)
Add
Compare
Today's Range
$9.83
$10.02
50-Day Range
$8.71
$10.72
52-Week Range
$8.68
$25.39
Volume34,511 shs
Average Volume3.41 million shs
Market Capitalization$2.66 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.15
30 days | 90 days | 365 days | Advanced Chart
Receive FOLD News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Amicus Therapeutics logo

About Amicus Therapeutics

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.37 out of 5 stars

Medical Sector

769th out of 2,101 stocks

Pharmaceutical Preparations Industry

384th out of 831 stocks

Analyst Opinion: 3.2Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Amicus Therapeutics (NASDAQ:FOLD) Frequently Asked Questions

Is Amicus Therapeutics a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There are currently 7 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amicus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FOLD, but not buy additional shares or sell existing shares.
View analyst ratings for Amicus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Amicus Therapeutics?

Wall Street analysts have given Amicus Therapeutics a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amicus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Amicus Therapeutics' next earnings date?

Amicus Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Amicus Therapeutics
.

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) posted its quarterly earnings results on Sunday, May, 9th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.01. The biopharmaceutical company had revenue of $66.40 million for the quarter, compared to analysts' expectations of $71.76 million. Amicus Therapeutics had a negative trailing twelve-month return on equity of 80.85% and a negative net margin of 95.05%.
View Amicus Therapeutics' earnings history
.

How has Amicus Therapeutics' stock been impacted by Coronavirus?

Amicus Therapeutics' stock was trading at $8.05 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FOLD stock has increased by 23.1% and is now trading at $9.91.
View which stocks have been most impacted by COVID-19
.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics updated its FY 2021 earnings guidance on Tuesday, June, 8th. The company provided earnings per share (EPS) guidance of $- for the period. The company issued revenue guidance of $300 million-315 million, compared to the consensus revenue estimate of $312.64 million.

What price target have analysts set for FOLD?

13 analysts have issued 1-year price objectives for Amicus Therapeutics' shares. Their forecasts range from $13.00 to $31.00. On average, they expect Amicus Therapeutics' share price to reach $20.42 in the next twelve months. This suggests a possible upside of 106.0% from the stock's current price.
View analysts' price targets for Amicus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Amicus Therapeutics' key executives?

Amicus Therapeutics' management team includes the following people:
  • Mr. John F. Crowley, Chairman & CEO (Age 54, Pay $2.06M)
  • Mr. Bradley L. Campbell M.B.A., Pres, COO & Director (Age 45, Pay $918.36k)
  • Ms. Daphne E. Quimi, Chief Financial Officer (Age 55, Pay $714.95k)
  • Dr. Hung Viet Do, Chief Scientific Officer (Age 53, Pay $646.12k)
  • Ms. Ellen S. Rosenberg, Chief Legal Officer & Corp. Sec. (Age 58, Pay $672.09k)
  • Ms. Samantha Prout, VP, Global Controller & Principal Accounting Officer (Age 43)
  • Andrew Faughnan, Sr. Director of Investor Relations
  • Mr. Patrik S. Florencio, Sr. VP, Global Chief Compliance & Risk Officer
  • Ms. Diana Moore, Head of Global Corp. Communications
  • Mr. David M. Clark, Chief People Officer (Age 46)

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics CEO John F. Crowley on Glassdoor.com. John F. Crowley has an approval rating of 48% among Amicus Therapeutics' employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amicus Therapeutics' key competitors?

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

What is Amicus Therapeutics' stock symbol?

Amicus Therapeutics trades on the NASDAQ under the ticker symbol "FOLD."

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (8.59%), BlackRock Inc. (8.09%), Redmile Group LLC (7.94%), Morgan Stanley (3.75%), Palo Alto Investors LP (3.67%) and Janus Henderson Group PLC (3.38%). Company insiders that own Amicus Therapeutics stock include Bradley L Campbell, Bradley L Campbell, Burke W Whitman, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends for Amicus Therapeutics
.

Which institutional investors are selling Amicus Therapeutics stock?

FOLD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Morgan Stanley, D. E. Shaw & Co. Inc., Janus Henderson Group PLC, Perceptive Advisors LLC, Bank of New York Mellon Corp, Nuveen Asset Management LLC, and BlackRock Inc.. Company insiders that have sold Amicus Therapeutics company stock in the last year include Bradley L Campbell, Daphne Quimi, Ellen Rosenberg, Hung Do, Jay Barth, John F Crowley, Margaret G Mcglynn, and Samantha Prout.
View insider buying and selling activity for Amicus Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Amicus Therapeutics stock?

FOLD stock was bought by a variety of institutional investors in the last quarter, including Fiera Capital Corp, Deerfield Management Company L.P. Series C, Palo Alto Investors LP, Healthcare of Ontario Pension Plan Trust Fund, Voloridge Investment Management LLC, Jennison Associates LLC, Grosvenor Holdings L.L.C., and New York State Common Retirement Fund. Company insiders that have bought Amicus Therapeutics stock in the last two years include Burke W Whitman, and Lynn Dorsey Bleil.
View insider buying and selling activity for Amicus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Amicus Therapeutics?

Shares of FOLD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amicus Therapeutics' stock price today?

One share of FOLD stock can currently be purchased for approximately $9.91.

How much money does Amicus Therapeutics make?

Amicus Therapeutics has a market capitalization of $2.64 billion and generates $260.89 million in revenue each year. The biopharmaceutical company earns $-276,850,000.00 in net income (profit) each year or ($1.04) on an earnings per share basis.

How many employees does Amicus Therapeutics have?

Amicus Therapeutics employs 483 workers across the globe.

What is Amicus Therapeutics' official website?

The official website for Amicus Therapeutics is www.amicusrx.com.

Where are Amicus Therapeutics' headquarters?

Amicus Therapeutics is headquartered at 1 Cedar Brook Drive, Cranbury NJ, 08512.

How can I contact Amicus Therapeutics?

Amicus Therapeutics' mailing address is 1 Cedar Brook Drive, Cranbury NJ, 08512. The biopharmaceutical company can be reached via phone at 609-662-2000 or via email at [email protected]


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.